trending Market Intelligence /marketintelligence/en/news-insights/trending/y5CGPufVmMKhGGtYWJD3ug2 content esgSubNav
In This List

Celltrion reports positive phase 3 results for breast cancer biosimilar

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Celltrion reports positive phase 3 results for breast cancer biosimilar

Biological medicine developer Celltrion Healthcare reported positive results from its phase 3 trial of CT-P6, a biosimilar of Roche Holding Ltd.'s Herceptin, in patients with early breast cancer and overexpression of HER2, a breast cancer development gene.

The pathological complete response rate at surgery, the primary endpoint, was 46.8% for CT-P6 and 50.4% for the reference blockbuster in the pre-protocol set.

Secondary endpoints were overall response rate, pharmacokinetics, pharmacodynamics and safety. CT-P6 and the reference product were similar in all secondary efficacy endpoints.

CT-P6 has been submitted to the European Medicines Agency for approval in all indications of the reference product. The biosimilar candidate is the second oncological biosimilar for Celltrion.